文献速递白血病

年龄与合并症对既往治疗慢性髓性白血病患者接受博舒替尼疗效与耐受性的影响:4期BYOND研究结果

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.
PubMed 文献 · Leukemia · 2023-11-25

4期BYOND试验中,156例既往治疗的费城染色体阳性慢性期慢性髓性白血病患者接受博舒替尼(起始剂量500 mg/天),随访≥3年后按年龄和改良Charlson合并症指数(mCCI)分析疗效与安全性。各年龄组和mCCI组中相当比例患者维持/获得细胞遗传学和分子学缓解,但≥75岁和mCCI≥4者治疗中出现的不良事件(TEAE)风险升高,可能需要更仔细的监测。

要点

  • 各年龄组任意时间累积主要分子学缓解率:<65岁73.6%、65-74岁64.5%、≥75岁74.1%。
  • mCCI 2、3、≥4组累积主要分子学缓解率分别为77.9%、63.0%、59.3%。
  • ≥75岁患者3/4级TEAE发生率96.4%、因不良事件永久停药率46.4%。

核心结论

  • 各年龄组和mCCI评分组中相当比例患者维持/获得细胞遗传学和分子学缓解。
  • ≥75岁患者和mCCI≥4的高合并症负担患者因TEAE风险增加可能需要更仔细的监测。

研究设计与样本

  • 4期BYOND试验(Clinicaltrials.gov: NCT02228382),既往治疗的费城染色体阳性慢性期慢性髓性白血病患者接受博舒替尼,起始剂量500 mg/天。
  • 报告156例患者随访≥3年后按年龄和改良Charlson合并症指数(不含年龄成分;mCCI)分析的疗效与安全性。

主要发现

  • 任意治疗时间累积主要分子学缓解率:<65岁73.6%、65-74岁64.5%、≥75岁74.1%;mCCI 2分77.9%、3分63.0%、≥4分59.3%。
  • 3/4级TEAE发生率:<65岁74.7%、65-74岁78.8%、≥75岁96.4%;mCCI 2分77.8%、3分77.8%、≥4分86.7%。
  • 因不良事件永久停药率:<65岁22.1%、65-74岁39.4%、≥75岁46.4%;mCCI 2分25.3%、3分33.3%、≥4分43.3%。

临床怎么用

  • 作者认为,≥75岁患者和mCCI≥4的高合并症负担患者因TEAE风险增加可能需要更仔细的监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 4 BYOND trial, patients with pretreated chronic myeloid leukemia (CML) received bosutinib (starting dose: 500 mg/day). Efficacy and safety after ≥3 years of follow-up in 156 patients with Philadelphia chromosome-positive chronic phase CML by age and Charlson Comorbidity Index scores (without the age component; mCCI) is reported. Cumulative major molecular response rates at any time on treatment were 73.6%, 64.5%, and 74.1% in patients <65, 65-74, and ≥75 years of age, and 77.9%, 63.0%, and 59.3% in patients with mCCI scores 2, 3, and ≥4, respectively. Patients <65, 65-74, and ≥75 years of age experienced grade 3/4 treatment-emergent adverse events (TEAEs) at rates of 74.7%, 78.8%, and 96.4% and permanent discontinuations due to AEs at rates of 22.1%, 39.4%, and 46.4%, respectively. In patients with mCCI 2, 3, and ≥4, respective rates of grade 3/4 TEAEs were 77.8%, 77.8%, and 86.7%, and permanent discontinuations due to AEs were 25.3%, 33.3%, and 43.3%. In conclusion, a substantial proportion of patients maintained/achieved cytogenetic and molecular responses across age groups and mCCI scores. Older patients (≥75 years) and those with high comorbidity burden (mCCI ≥4) may require more careful monitoring due to the increased risk of TEAEs. Clinicaltrials.gov: NCT02228382.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Rosti G, Brümmendorf TH, Gjertsen BT, et al. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. Leukemia. 2023. PMID: 38007586. doi:10.1038/s41375-023-02080-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。